Antimicrobial Agents and Novel Vaccines

Vaccines can reduce the prevalence of resistance by reducing the need for antimicrobial use and can reduce its impact by reducing the total number of cases. By reducing the number of pathogens that may be responsible for a particular clinical syndrome, vaccines can permit the use of narrower-spectrum antibiotics for empirical therapy. These effects may be amplified by herd immunity, extending protection to unvaccinated persons in the population. Because much selection for resistance is due to selection on bystander members of the normal flora, vaccination can reduce pressure for resistance even in pathogens not included in the vaccine. Some vaccines have had disproportionate effects on drug-resistant lineages within the target species, a benefit that could be more deliberately exploited in vaccine design.

 

  • Hib conjugate vaccine
  • Respiratory virus vaccine

Related Conference of Antimicrobial Agents and Novel Vaccines

June 02-03, 2025

14th World Congress on Rare Diseases and Orphan Drugs

Amsterdam, Netherlands
June 02-03, 2025

17th Euro-Global Conference on Infectious Diseases

Amsterdam, Netherlands
August 28-29, 2025

8th Pathology and Infectious Disease Conference

London, UK
September 22-23, 2025

11th International Conference on Infectious and Rare Diseases

Vancouver, Canada
December 11-12, 2025

8th Annual Congress on Bacterial, Viral and Infectious Diseases

Prague, Czech Republic

Antimicrobial Agents and Novel Vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in